Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

6.15EUR
12:56pm BST
Change (% chg)

€1.36 (+28.39%)
Prev Close
€4.79
Open
€5.99
Day's High
€6.29
Day's Low
€5.70
Volume
2,186,017
Avg. Vol
105,760
52-wk High
€10.10
52-wk Low
€4.33

Chart for

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.11
Market Cap(Mil.): €603.39
Shares Outstanding(Mil.): 57.36
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -0.14 -- --
ROI: -4.04 0.21 14.27
ROE: -10.93 1.17 15.99

AstraZeneca digs deeper into cancer with Innate stake

LONDON/PARIS AstraZeneca is ploughing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma , which includes the British group buying a 9.8 percent stake in the French biotech company.

12:34pm BST

AstraZeneca digs deeper into cancer with Innate stake

LONDON/PARIS AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

9:16am BST

UPDATE 2-AstraZeneca digs deeper into cancer with Innate stake

* Innate shares jump 29 percent (Updates with executive interviews, latest shares)

9:05am BST

French and Benelux stocks-Factors to watch on Oct 23

Oct 23 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

7:12am BST

AstraZeneca to buy 9.8 pct stake in France's Innate Pharma

PARIS, Oct 23 British drugmaker AstraZeneca will buy a newly-issued equity stake of 9.8 percent in smaller French peer Innate Pharma, strengthening its presence in the field of immuno-oncology.

6:17am BST

BRIEF-Innate Pharma: Phase II Results From Monalizumab/Cetuximab In Head And Neck Cancer

* INNATE PHARMA ANNOUNCED ON SATURDAY PHASE II RESULTS FROM MONALIZUMAB/CETUXIMAB IN HEAD AND NECK CANCER

22 Oct 2018

BRIEF-Innate Pharma Publishes Phase 1 IPH4102 Results

* REPORTED ON SATURDAY IPH4102 PHASE 1 RESULTS IN ADVANCED CUTEANOUS T CELL LYMPHOMA

01 Oct 2018

Earnings vs. Estimates